| __timestamp | Neurocrine Biosciences, Inc. | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 17986000 | 4241601.57 |
| Thursday, January 1, 2015 | 32480000 | 5392385.38 |
| Friday, January 1, 2016 | 68081000 | 7370036.73 |
| Sunday, January 1, 2017 | 169906000 | 14970357 |
| Monday, January 1, 2018 | 248932000 | 31413266 |
| Tuesday, January 1, 2019 | 354100000 | 72279461 |
| Wednesday, January 1, 2020 | 433300000 | 183907682 |
| Friday, January 1, 2021 | 583300000 | 307644000 |
| Saturday, January 1, 2022 | 752700000 | 472132000 |
| Sunday, January 1, 2023 | 887600000 | 709539000 |
| Monday, January 1, 2024 | 1007200000 |
Unleashing insights
In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Neurocrine Biosciences, Inc. and argenx SE have showcased distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Neurocrine's SG&A expenses surged by nearly 4,800%, reflecting its aggressive expansion and market penetration strategies. In contrast, argenx SE, while starting from a lower base, exhibited a remarkable growth of over 16,600% in the same period, underscoring its rapid scaling and operational investments. By 2023, Neurocrine's SG&A expenses reached approximately 1.25 times that of argenx, highlighting its sustained financial commitment to growth. This comparison not only illustrates the companies' strategic priorities but also offers insights into their competitive positioning in the biotech sector. As these companies continue to evolve, their financial strategies will remain pivotal in shaping their future trajectories.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: argenx SE vs Teva Pharmaceutical Industries Limited
Breaking Down SG&A Expenses: argenx SE vs Intra-Cellular Therapies, Inc.
Who Optimizes SG&A Costs Better? argenx SE or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of argenx SE and Viking Therapeutics, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends